Christopher Dinsmore - Sep 7, 2021 Form 4 Insider Report for Kronos Bio, Inc. (KRON)

Role
Chief Scientific Officer
Signature
/s/ Allison Frisbee, Attorney-in-Fact
Stock symbol
KRON
Transactions as of
Sep 7, 2021
Transactions value $
-$171,254
Form type
4
Date filed
9/9/2021, 01:23 PM
Previous filing
Aug 3, 2021
Next filing
Oct 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRON Common Stock Options Exercise $30K +9.19K +9.54% $3.27 106K Sep 7, 2021 Direct
transaction KRON Common Stock Sale -$201K -9.19K -8.71% $21.91* 96.4K Sep 7, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRON Employee Stock Option (Right to Buy) Options Exercise $0 -9.19K -2.75% $0.00 324K Sep 7, 2021 Common Stock 9.19K $3.27 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2021.
F2 The weighted average sale price for the transaction reported was $21.9068, and the range of prices were between $20.85 and $22.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 Immediately exercisable.